News from immusant, inc

Sep 09, 2013, 08:00 ET
ImmusanT logo.  (PRNewsFoto/ImmusanT, Inc.)

ImmusanT Names Ferdinand E. Massari as Chief Medical Officer

ImmusanT announced today that Ferdinand E. Massari, MD has joined the biopharmaceutical company as Senior Vice President, Development and Chief...

Aug 27, 2013, 19:00 ET

New Approach to Celiac Testing Identifies More Patients at Risk

 Researchers have developed a new approach to detecting unrecognized cases of celiac disease in the community, revealing this immune disorder...

Aug 06, 2013, 08:00 ET

ImmusanT Initiates Study at Joslin Diabetes Center to Investigate Relationship Between Celiac Disease and Type 1 Diabetes

 ImmusanT today announced that it has initiated a clinical research study to explore the immunologic relationship between celiac disease and...

Apr 19, 2013, 11:43 ET

ImmusanT's Epitope-Specific Immunotherapy for Celiac Disease Informs the Potential of Vaccines Against Other Autoimmune Diseases

In autoimmune disorders such as celiac disease and Type 1 diabetes, the body's immune system attacks its own cells. Current treatments for many...

Oct 11, 2012, 12:21 ET

Link Between Gluten and Immune Reaction Revealed for HLA-DQ8 Celiac Disease

A link between gluten and the immune system has literally been visualized in new research published today in a leading scientific journal,...

Sep 04, 2012, 08:00 ET

ImmusanT Initiates Clinical Trials of Nexvax2 Therapeutic Vaccine for Celiac Disease

 ImmusanT announced today that it has initiated clinical trials in New Zealand, Australia and the U.S. to evaluate Nexvax2®, the first...

Aug 16, 2012, 08:00 ET

ImmusanT Relocates Offices to State-of-the-Art Innovation Facility

ImmusanT, Inc. announced today that it has relocated its operations to One Kendall Square, a 676,000-square-foot, mixed-use campus in the heart...

Mar 19, 2012, 08:00 ET

ImmusanT Names Patrick Griffin as Chief Medical Officer, Expands Management Team

ImmusanT announced today that Patrick H. Griffin, MD, has joined the biopharmaceutical company as Chief Medical Officer and Senior Vice President...

Dec 13, 2011, 07:00 ET

ImmusanT Raises $20 Million in Series A Financing to Advance Immunotherapeutic and Diagnostic for Celiac Disease

ImmusanT, Inc. announced today it has raised $20 million in Series A financing from Vatera Healthcare Partners LLC to advance development of the...

May 09, 2011, 08:00 ET

ImmusanT Reports Positive Results from Nexvax2 Phase 1 Study in Celiac Disease

ImmusanT, Inc., a biotechnology company developing an immunotherapeutic vaccine, companion diagnostic and monitoring tool for celiac disease,...

Mar 15, 2011, 08:00 ET

Start-Up ImmusanT Seeks to Restore Tolerance to Gluten in Celiac Disease with Immunotherapy

Biotechnology company ImmusanT, Inc. today announced it has established its operations in Cambridge, Massachusetts and is advancing its strategy to...

Organizations in the News

The organizations with the most activity in PR Newswire's News Room

ReportBuyer
Research and Markets
Investor-Edge